Last reviewed 2026-05-15 · How we verify

Cyclophosphamide Capsules

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Neutropenia
• Anaemia
• Diarrhoea
• Fatigue
• Alopecia
• Constipation
• Vomiting
• Pyrexia
• Leukopenia
• Thrombocytopenia
• Cough

Key clinical trials

• A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (PHASE2)
• Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (PHASE2)
• Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (PHASE1, PHASE2)
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (PHASE2)
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (PHASE3)
• Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population (PHASE2)
• UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (PHASE3)
• Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Cyclophosphamide Capsules CI brief — competitive landscape report
• Cyclophosphamide Capsules updates RSS · CI watch RSS
• Fujian Cancer Hospital portfolio CI